Table of Content

Introduction
Executive Summary
Acute myeloid leukaemia: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Acute myeloid leukaemia – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
• Comparative Analysis
Volasertib: Boehringer Ingelheim
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Mid Stage Products (Phase II)
• Comparative Analysis
BST-236: BioSight
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Early Stage Products (Phase I)
• Comparative Analysis
DSP 5336: Sumitomo Dainippon Pharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..

Preclinical and Discovery Stage Products
• Comparative Analysis
IPH 6101: Innate Pharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Inactive Products
• Comparative Analysis
Acute myeloid leukaemia Key Companies
Acute myeloid leukaemia Key Products
Acute myeloid leukaemia- Unmet Needs
Acute myeloid leukaemia- Market Drivers and Barriers
Acute myeloid leukaemia- Future Perspectives and Conclusion
Acute myeloid leukaemia Analyst Views
Acute myeloid leukaemia Key Companies
Appendix



List of Figures

Figure 1 Total Products for Acute myeloid leukaemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

List of Tables

Table 1 Total Products for Acute myeloid leukaemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products